Wells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably alrea

September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a

Tidal Investments LLC lifted its position in argenex SE (NASDAQ: ARGX) by 97.8% in the second quarte

argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintain

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized ba

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintain

TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and dev

Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal c

September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology

Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises th

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 2

UBS analyst Xian Deng upgrades argenx (NASDAQ:ARGX) from Neutral to Buy and raises the price targ

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the

Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earn

Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While

argenx (NASDAQ: ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting it

Truist Securities analyst Danielle Brill maintains argenx (NASDAQ:ARGX) with a Buy and raises the

argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune

RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and raises the pri

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Argenx SE (NASDAQ:ARGX) on Monday disclosed positive topline results from its Phase 3 ALKIVIA study.

Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis.

Citizens analyst Jason N. Butler maintains argenx (NASDAQ:ARGX) with a Market Outperform and rais

Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises th

HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and raises

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's reg

US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consu

Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises

argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART H

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.49% on an annualized ba

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers i

Argenx stock surges 12% as VYVGART Hytrulo hits Phase 3 ALKIVIA endpoint in autoimmune myositis, sho

SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688)

Belgian-Dutch immunology company argenx ARGX.BR said its drug efgartigimod met the primary endpoint

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study po

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study po

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized bas

argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that A

Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises th

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consume

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expa

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and tec

Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and raises the price tar

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a discip